255 related articles for article (PubMed ID: 2468279)
1. Prostate-specific antigen in prostatic cancer.
Baron JC; Peyret C; Leroy M; Teillac P; Najean Y; Le Duc A
Am J Clin Oncol; 1988; 11 Suppl 2():S75-6. PubMed ID: 2468279
[TBL] [Abstract][Full Text] [Related]
2. The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer.
Armitage TG; Cooper EH; Newling DW; Robinson MR; Appleyard I
Br J Urol; 1988 Dec; 62(6):584-9. PubMed ID: 2464397
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen (PSA) in the management of 500 prostatic patients.
Guillet J; Role C; Duc AT; François H
Am J Clin Oncol; 1988; 11 Suppl 2():S61-2. PubMed ID: 2468274
[TBL] [Abstract][Full Text] [Related]
4. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
[TBL] [Abstract][Full Text] [Related]
5. Serum prostate-specific antigen determination in prostatic carcinoma.
Tizzani A; Casetta G; Piana P; Bellina M; Pecchio F; Aimo G; Adamo R
Int J Biol Markers; 1987; 2(3):184-6. PubMed ID: 2453594
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease.
Buamah PK; Johnson P; Skillen AW
Br J Urol; 1988 Dec; 62(6):581-3. PubMed ID: 2464396
[TBL] [Abstract][Full Text] [Related]
7. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer.
Benson MC; Whang IS; Pantuck A; Ring K; Kaplan SA; Olsson CA; Cooner WH
J Urol; 1992 Mar; 147(3 Pt 2):815-6. PubMed ID: 1371554
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and discriminative ability of prostate-specific antigen as a tumor marker.
Leitenberger A; Altwein JE
Eur Urol; 1990; 17(1):12-6. PubMed ID: 1690653
[TBL] [Abstract][Full Text] [Related]
9. The usefulness of prostate-specific antigen and prostatic acid phosphatase in clinical practice.
Daver A; Soret JY; Coblentz Y; Allain YM; Cellier P; Chauveau P
Am J Clin Oncol; 1988; 11 Suppl 2():S53-60. PubMed ID: 2468273
[TBL] [Abstract][Full Text] [Related]
10. Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy.
Marrink J; Oosterom R; Bonfrer HM; Schröder FH; Mensink HJ
Eur J Cancer; 1993; 29A(4):570-1. PubMed ID: 7679580
[TBL] [Abstract][Full Text] [Related]
11. Significance of PSA and PAP in patients with or without prostatic cancer.
Caty A; Gosselin P; Cazin JL; Dehaut JM; Adenis L
Am J Clin Oncol; 1988; 11 Suppl 2():S63-4. PubMed ID: 2468275
[TBL] [Abstract][Full Text] [Related]
12. Comparison of prostate-specific antigen and prostatic acid phosphatase in the management of prostatic cancer.
Turkes A; Nott J; Turkes AO; Griffiths K
Am J Clin Oncol; 1988; 11 Suppl 2():S77-9. PubMed ID: 2468280
[TBL] [Abstract][Full Text] [Related]
13. Is prostate-specific antigen the most useful marker for screening in prostate cancer?
Delaere KP; Van Dieijen-Visser MP; Gijzen AH; Brombacher PJ
Am J Clin Oncol; 1988; 11 Suppl 2():S65-7. PubMed ID: 2468276
[TBL] [Abstract][Full Text] [Related]
14. [Anatomoclinical and biologic correlations in prostatic pathology. Apropos of 150 case reports].
Amiel J; Chevallier D; Peyrottes A; Benoliel J; Toubol J
Ann Urol (Paris); 1989; 23(6):528-30. PubMed ID: 2482700
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.
Carter HB; Pearson JD; Metter EJ; Brant LJ; Chan DW; Andres R; Fozard JL; Walsh PC
JAMA; 1992 Apr 22-29; 267(16):2215-20. PubMed ID: 1372942
[TBL] [Abstract][Full Text] [Related]
16. [A comparison between prostate-acid-phosphatase and prostate-specific antigen in the diagnosis of prostatic carcinoma].
Bentvelsen FM; Bogdanowicz JF; Oosterom R; Schröder FH
Ned Tijdschr Geneeskd; 1990 Aug; 134(33):1596-600. PubMed ID: 1697651
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of prostate-specific antigen density as a diagnostic test of prostate cancer.
Filella X; Alcover J; Molina R; Carrere W; Carretero P; Ballesta AM
Tumour Biol; 1996; 17(1):20-6. PubMed ID: 7501969
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
20. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
Tarle M; Kraljić I
Anticancer Res; 1997; 17(3A):1531-4. PubMed ID: 9179191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
